APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists for Vasomotor Symptoms

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurokinin Receptor Antagonists for Vasomotor Symptoms market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurokinin Receptor Antagonists for Vasomotor Symptoms market include Astellas Pharma and Bayer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurokinin Receptor Antagonists for Vasomotor Symptoms and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurokinin Receptor Antagonists for Vasomotor Symptoms market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Company

Astellas Pharma

Bayer

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant

Elinzanetant

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic

Pharmacy

Other

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurokinin Receptor Antagonists for Vasomotor Symptoms status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurokinin Receptor Antagonists for Vasomotor Symptoms market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurokinin Receptor Antagonists for Vasomotor Symptoms significant trends, drivers, influence factors in global and regions.

6. To analyze Neurokinin Receptor Antagonists for Vasomotor Symptoms competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurokinin Receptor Antagonists for Vasomotor Symptoms market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurokinin Receptor Antagonists for Vasomotor Symptoms industry.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurokinin Receptor Antagonists for Vasomotor Symptoms in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends Table 2. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers Table 3. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges Table 4. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints Table 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Company (2021-2026) Table 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Company (2021-2026) Table 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Company Manufacturing Base & Headquarters Table 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company, Product Type & Application Table 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Fezolinetant Table 18. Significant Companies of Elinzanetant Table 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Type (2021-2026) Table 23. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Type (2027-2032) Table 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type (2021-2026) Table 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Application (2021-2026) Table 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Application (2027-2032) Table 37. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application (2021-2026) Table 41. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application (2027-2032) Table 42. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units) Table 44. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2026) Table 45. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032) & (K Units) Table 46. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2027-2032) Table 47. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Region (2021-2026) Table 50. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Region (2027-2032) Table 52. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 57. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 58. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 59. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2027-2032) Table 60. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Market Share by Country (2021-2026) Table 62. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Market Share by Country (2027-2032) Table 64. Astellas Pharma Company Information Table 65. Astellas Pharma Business Overview Table 66. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 68. Astellas Pharma Recent Development Table 69. Bayer Company Information Table 70. Bayer Business Overview Table 71. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 73. Bayer Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List Table 77. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Image Figure 2. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032) & (K Units) Figure 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Fezolinetant Image Figure 10. Elinzanetant Image Figure 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Type (2021-2032) Figure 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Application (2021-2032) Figure 23. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application (2021-2032) Figure 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 31. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 37. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Fezolinetant
  • Elinzanetant
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Astellas Pharma
  • Bayer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  4. 1.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume (2021-2032)
  5. 1.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Dynamics
  1. 2.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
  2. 2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
  3. 2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
  4. 2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Company
  1. 3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Revenue Ranking in 2025
  2. 3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Company (2021-2026)
  3. 3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price by Company (2021-2026)
  5. 3.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Ranking (2024-2026)
  6. 3.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Product Type and Application
  8. 3.8 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurokinin Receptor Antagonists for Vasomotor Symptoms Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
  1. 4.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Type Introduction
  2. 4.1.1 Fezolinetant
  3. 4.1.2 Elinzanetant
  4. 4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type
  5. 4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type
  9. 4.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Type (2021-2032)
  11. 4.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type (2021-2032)
5 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
  1. 5.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application
  6. 5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application
  10. 5.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application (2021-2032)
6 Neurokinin Receptor Antagonists for Vasomotor Symptoms Regional Sales and Value Analysis
  1. 6.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2032)
  3. 6.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021-2026
  4. 6.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032)
  5. 6.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Region (2027-2032)
  9. 6.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  12. 6.6.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  15. 6.7.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  21. 6.9.2 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Country, 2025 VS 2032
7 Neurokinin Receptor Antagonists for Vasomotor Symptoms Country-level Sales and Value Analysis
  1. 7.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  4. 7.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  5. 7.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032)
  6. 7.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  12. 8.2.5 Bayer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
  2. 9.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Mode & Process
  6. 9.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
  9. 9.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst